Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 29 July

Sophia Mavridis
July 29, 2022

Morning Bell 28 July

Paulina Peters
July 28, 2022

Morning Bell 27 July

Paulina Peters
July 27, 2022

Morning Bell 26 July

Sophia Mavridis
July 26, 2022

Morning Bell 25 July

Sophia Mavridis
July 25, 2022

Weekly Wrap 22 July

Sophia Mavridis
July 22, 2022

Morning Bell 21 July

Paulina Peters
July 21, 2022

Morning Bell 20 July

Sophia Mavridis
July 20, 2022

Morning Bell 19 July

Paulina Peters
July 19, 2022

Morning Bell 18 July

Sophia Mavridis
July 18, 2022

Weekly Wrap 15 July

Sophia Mavridis
July 15, 2022

Morning Bell 14 July

Paulina Peters
July 14, 2022